• Depomed Inc., of Menlo Park, Calif., presented additional data from its Phase III trial, BREEZE 3, suggesting Serada, its nonhormonal extended-release formulation of gabapentin, may help manage menopausal hot flashes.
To continue reading subscribe now to BioWorld Today
